Emerging Insights and New Therapeutic Opportunities: Acne and Atopic Dermatitis

The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris

Combination Therapy Considerations in Acne Vulgaris

Evolving Therapy in Atopic Dermatitis

Nonsteroidal Treatment of Atopic Dermatitis

FACULTY

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis, School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children’s Hospital
San Diego

Leon Kircik, MD
Clinical Associate Professor
Department of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis

Produced in affiliation with the 30th Annual Hawaii Dermatology Seminar™
Emerging Insights and New Therapeutic Opportunities: Acne and Atopic Dermatitis

Topic Highlights

Introduction 3

The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris 3

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology, University of California, Davis, School of Medicine
Medical Director, Center for Dermatology and Laser Surgery, Sacramento

Combination Therapy Considerations in Acne Vulgaris 6

Leon Kircik, MD
Clinical Associate Professor, Department of Dermatology, Indiana University, Indianapolis
Medical Director, Physicians Skin Care, PLLC, Louisville, Ky.

Evolving Therapy in Atopic Dermatitis 8

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology), University of California San Diego, School of Medicine
Children's Hospital, San Diego

Nonsteroidal Treatment of Atopic Dermatitis 10

James Turner, MD, PhD
Clinical Professor, Division of Dermatology, Department of Medicine University of Tennessee, Memphis

TARGET AUDIENCE
This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

FACULTY AND UNAPPROVED/OFF-LABEL USE DISCLOSURES
Faculty/authors must disclose any significant financial interest or relationship with proprietary entities that may have a direct relationship to the subject matter. They must also disclose any discussion of investigational or unlabeled uses of products.

Dr Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermaceuticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

Dr Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucentx Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1%/benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Dr Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Dr Turner has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

The supplement was produced by the medical education department of International Medical News Group. Neither the Editor of Pediatric News, the Editorial Advisory Board, nor the reporting staff reviewed or contributed to its contents. The opinions expressed in this supplement are those of the faculty and do not necessarily reflect the views of the supporter or the Publisher.

Copyright © 2006 Elsevier, Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Elsevier, Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
In this supplement, which is based on an educational symposium held at Skin Disease Education Foundation’s 30th Hawaii Dermatology Seminar, the faculty discusses the clinical management of patients with acne vulgaris and atopic dermatitis (AD). Both conditions present a significant challenge to dermatologists due to their complex pathogenesis and range of clinical expression. Because of the widespread prevalence and chronicity of acne and AD, it is necessary to provide patients with treatments that are effective and well tolerated. Paramount to these goals is the effectiveness of the vehicle formulation in protecting skin barrier function. Attention to barrier function allows the beneficial effects of treatment regimens for acne and AD to be maximized.

A number of studies focusing on acne therapy demonstrate the importance of skin rehydration and maintaining the integrity of the skin barrier. In the studies presented, the two most effective gels used to treat acne contain the active ingredients clindamycin 1% and benzoyl peroxide (BPO) 5%. One gel provides the clindamycin/BPO combination in a drug-delivery vehicle containing the emollients glycerin 4% and dimethicone 1%. The second gel contains the active agents without emollients. The advantages of combination therapy and the importance of vehicle to enhance barrier function are discussed.

The complex etiology of AD is reviewed and the importance of skin barrier function is emphasized. Standard therapies for AD include emollients, corticosteroids (topical and systemic), antibiotics, antihistamines, and bathing regimens. Topical calcineurin inhibitors have been added as second-line agents in the treatment of AD. Newer additions to the AD treatment armamentarium are presented, including a nonsteroidal cream that provides stratum corneum repair, skin hydration, lipid modification, and alleviation of AD symptoms. A discussion of a new glycyrrhetinic acid–based formulation with anti-inflammatory and antipruritic properties is included. Encouraging results with probiotics are also presented.

The treatment of barrier dysfunction as an evolving area of therapy for both acne vulgaris and AD is addressed in the following pages. The pathogenesis of these disorders and treatment regimens typically contribute to the disruption of the epidermal barrier. The faculty underscores the importance of hydration of the stratum corneum with moisturizing agents to re-establish the integrity of skin barrier function, which ultimately improves the tolerability of acne and AD therapy and optimizes treatment outcomes.
In addition to efficacy and safety, several important factors are desirable in a topical medication. The ideal vehicle allows the patient to spread the medication evenly over the skin, depositing an even, thin film. In addition, to avoid contamination of the medication, a tube dispenser offers an advantage over a jar. Finally, it is an advantage if the medication can be dispensed from a container that delivers the proper amount of medication.

Enhancing Barrier Function
Currently, key areas of focus for both clinicians and researchers are the composition of various acne treatments, their effect on skin function, and the potential for skin irritation. For example, benzoyl peroxide (BPO) and topical retinoids are inherently drying, and this drying effect is accentuated in patients with sensitive skin. Improved acne medication vehicles help reduce or minimize the drying effect of some of these medications.

Improvement of the barrier function of the skin involves rehydration of the stratum corneum. This can be accomplished via two pharmaceutical approaches. The first is to add an occlusive moisturizing agent to the vehicle to trap water and inhibit loss of moisture. The second approach is to use a humectant agent to attract moisture to the stratum corneum from the lower epidermal and dermal layers. Occlusive agents act as skin moisturizers by reducing the evaporation of water into the atmosphere. Typically, occlusives are oily substances such as hydrocarbon oils and waxes and vegetable and animal fats, which may be comedogenic in some patients. Silicone products such as dimethicone and cyclomethicone are commonly used in acne vehicles because they are “oil-free” agents that are hypoallergenic, noncomedogenic, and fragrance-free. As noted, humectants draw water to the stratum corneum from the deeper layers of the epidermis and dermis. Humectants include a number of agents such as glycerin, sodium lactate, urea, and propylene glycol. The substances most widely used today, glycerin and urea, are well tolerated and effective. Table 2 lists the most commonly used occlusive moisturizers and humectants.

**Vehicle Affects Tolerability**
Using an occlusive agent alone will not draw moisture to the epidermis, and a humectant alone will increase transepidermal water loss. Therefore, the most effective vehicle for acne therapy should combine both a humectant and an occlusive agent.

An optimum vehicle also should not produce adverse sensory stimuli such as a burning sensation. Patients find products that “burn” very difficult to use and will often stop using such a product within a day or two. Antibacterial activity is another consideration in topical acne treatment. Clindamycin is an excellent topical antimicrobial agent and is less drying than other topical agents, such as BPO. However, clindamycin recently has become less effective because of the emergence of bacterial
After the washout period, the patients used one gel for 2 weeks, followed by a 2-week washout period when acne was present. Each patient used one gel for 2 weeks, with mild to moderate acne (mean age 21 years) with mild to moderate acne. A total of 61 patients completed the weeklong study. Local tolerance was graded by a blinded evaluator and by the patients using the emollient-based gel was better tolerated, with substantially less dryness and burning compared to baseline. There was no significant difference in erythema between the two groups.

The first of these studies, by Fagundes and colleagues, was a randomized, evaluator-blinded, split-face trial. The patients were between 15 and 25 years of age, all with mild acne. A total of 61 patients completed the weeklong study. Local tolerance was graded by a blinded evaluator and by patients at baseline and at the end of 1 week.

The results of the study demonstrated that the emollient-based gel was better tolerated, with substantially less dryness (P<0.05) and significantly less peeling (P=0.045) and burning (P=0.034) among the patients using the emollient-based product. There was no significant difference in erythema between the two groups.

In the second tolerability study, the two combination gels, with and without emollients, were evaluated in 52 patients (mean age 21 years) with mild to moderate acne. Each patient used one gel for 2 weeks, followed by a 2-week washout period when all acne medications were discontinued. After the washout period, the patients used the second gel for 2 weeks. The investigators determined the degree of peeling and observed dryness. Both factors, which are manifestations of barrier dysfunction, were judged as “worse” or as “the same or improved” compared to baseline. The patients also evaluated dryness before and during the use of each gel.

After 2 weeks, the patients reported that use of the gel with emollients was associated with significantly less dryness and peeling (P<0.05) and said they experienced significantly better local tolerability with the emollient-containing formulation (P<0.05).

### Improving Tolerability of Retinoid Therapy

The benefit of moisturizer-containing vehicles was demonstrated in patients with mild to moderate acne during retinoid therapy. In a 12-week study, 121 patients received tazarotene with vehicle only (n=61) or a combination product containing tazarotene plus clindamycin, BPO, and an emollient (T+CBE). At week 12, there were differences in peeling and dryness that were seen between tazarotene alone and T+CBE combination which did not achieve statistical significance. However, at week 4, patients who received the T+CBE formulation experienced significantly less peeling (P<0.05) (Figure).

This last finding is particularly important because, during the first 4 to 6 weeks of retinoid therapy, skin barrier dysfunction—and associated patient discomfort—is highest due to retinization. After this period, barrier function improves and dryness and peeling often diminish significantly.

This study suggests that using a T+CBE combination medication improves tolerability during retinoid therapy. Poor tolerability often leads to cessation of use of effective topical therapy during the first 4 weeks of retinoid treatment, when symptoms of barrier dysfunction are most likely to be bothersome. Improving tolerability may lead to enhanced compliance during this crucial time.

### Summary

Attention to improved barrier function is essential for successful treatment and outcomes in patients with acne vulgaris and other dermatologic disorders. To enhance hydration, a vehicle that combines an occlusive agent and a humectant moisturizer is ideal. Combination therapy for acne, with the addition of moisturizers such as dimethicone and glycerin, enhances barrier function and will improve treatment outcomes. This is especially important during treatment with topical retinoids. Clinicians should consider the choice of active ingredients as well as vehicle, as both are equally important in the successful management of patients with acne vulgaris.

### References

Acne vulgaris is one of the most common skin disorders seen in clinical practice. The most successful strategy to treat acne requires careful patient evaluation and combination treatment.

**Etiology and Pathogenesis**

Acne vulgaris affects approximately 85% of Americans. The cause of acne vulgaris is unknown, but various factors have been implicated in its pathogenesis. The primary change in acne lesions is an alteration in the pattern of keratinization within the follicle. Normally, keratinous material in the follicle is loosely organized. There are a large number of lamellar granules and relatively few keratohyaline granules. In comedones, the keratinous material becomes more dense, lamellar granules decrease, and keratohyaline granules increase.

In addition, individuals with acne have larger sebaceous glands and increased sebum production. Sebum is comedogenic, and sebum induces inflammation. Also, patients with acne have decreased levels of linoleic acid. This decrease leads to localized essential fatty acid deficiency of the follicular epithelium, which may result in follicular hyperkeratosis and decreased epithelial barrier function.

Other factors affecting sebaceous glands include insulin-like growth factors, growth hormone, androgens and estrogens, peroxisome proliferator–activated receptors, and melanocortins.

The inflammatory process associated with Propionibacterium acnes is an important underlying mechanism in acne. Several mechanisms have been identified that are associated with P. acnes (Table 1).

<table>
<thead>
<tr>
<th><strong>Table 1. Inflammation and P. acnes</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Propionibacterium acnes induces inflammation in the following ways:</strong></td>
</tr>
<tr>
<td>• Releases lipases, proteases, and hyaluronidases</td>
</tr>
<tr>
<td>• Secretes chemotactic factors</td>
</tr>
<tr>
<td>• Activates both classical and alternative complement pathways</td>
</tr>
<tr>
<td>• Stimulates cytokine release by monocytes</td>
</tr>
</tbody>
</table>

P. acnes = Propionibacterium acnes

Polymorphonuclear neutrophils (PMNs) surrounding the follicle. Proinflammatory cytokines (IL-1β, IL-8, and tumor necrosis factor–α) released by PMNs upon activation with P. acnes may produce inflammation.

**Rationale for Combination Therapy**

Because many factors are related to the pathogenesis of acne, combination therapy appears to be the most effective therapeutic approach. Combination therapy targets multiple pathologic processes, establishes synergy among individual agents, and overcomes limitations associated with monotherapy. Increasing efficacy, improving patient compliance, enhancing tolerability, and minimizing complications are the goals for combination therapy.

Synergy among available acne combination therapies results when there is significant overlap in the mechanistic activities of the agents. Table 2 summarizes the mechanism of action of both topical and oral agents. When used in combination, these therapies have overlapping mechanism of actions that enhance therapeutic efficacy.

Normalization of follicular epithelial shedding is the primary mechanism of action of topical retinoids and salicylic acid. Benzoyl peroxide (BPO) and azelaic acid act primarily to reduce the number of P. acnes organisms, and both agents have comedolytic properties. Topical antibiotics act to reduce P. acnes; so using a topical retinoid along with a topical antibiotic/BPO combination—each with a different mechanism of action—effectively addresses multifactorial pathogenesis of acne vulgaris.

BPO is available in over-the-counter and prescription formulations in strengths ranging from 2.5% to 10%. BPO monotherapy is most useful for treating mild acne. Its mechanism appears to be related to bactericidal effects and comedolytic activity. Irritation, dry skin, and bleaching
of skin or fabrics may occur, and some patients find these side effects intolerable. Contact dermatitis has been reported but is relatively rare.

Topical retinoids such as tretinoin, adapalene, and tazarotene can all be used to treat comedonal and inflammatory lesions. They can be used as monotherapy or with topical antibiotics—that is, given alone or in combination (alternating) with topical antibiotics to enhance efficacy. All of these topical agents normalize keratinization; however, adapalene and tazarotene appear to have additional anti-inflammatory properties. Adverse effects include skin irritation, particularly with higher-concentration formulations. Also, retinoids typically are associated with photosensitivity and acne flare during the early weeks of therapy.

Efficacy of Antibiotic/BPO Combinations

BPO therapy is effective for patients with acne, and, in some cases, BPO monotherapy is more effective in the reduction of P. acnes than is topical clindamycin or erythromycin alone. The highest reduction in P. acnes is achieved with the clindamycin/BPO combination; the combination offers slightly better reduction of P. acnes as compared to BPO alone, with the added benefit of inhibiting the development of erythromycin- and clindamycin-resistant P. acnes strains.

Two pivotal studies examined the effects of clindamycin/BPO combination gel. The treatment arms used were clindamycin 1%/BPO 5% gel, clindamycin 1% gel, BPO 5% gel, and vehicle. The two studies were double-blind, randomized, vehicle-controlled trials in which patients were treated for 10 weeks with twice-daily application of the agent. A total of 767 subjects with moderate to moderately severe acne completed the studies.

The results of the studies demonstrated that the clindamycin/BPO combination was more effective than BPO, clindamycin, or vehicle alone. One of the studies showed that combination therapy outperformed other treatment arms for both noninflammatory and inflammatory lesions.

In two subsequent trials, Lookingbill and colleagues also evaluated the clindamycin/BPO combination versus the use of single agents and vehicle. The study was an 11-week, double-blind, randomized, parallel, vehicle-controlled trial with once-nightly application of the study drug. The four treatment arms were clindamycin 1%/BPO 5% gel with moisturizers, (Duac) clindamycin 1% gel, vehicle, and BPO 5% gel. Three hundred thirty-four subjects with acne between 13 and 30 years of age completed the studies. The investigators found that all three active treatments outperformed vehicle with differences that were statistically significant (P≤0.004). In addition, both the combination therapy and BPO alone were significantly superior to clindamycin alone (P≤0.01).

The data from Lookingbill and colleagues also showed that combination therapy was superior in reducing noninflammatory lesions. A mean reduction of 36% in noninflammatory lesions was shown in patients (n=95) who used the clindamycin/BPO combination in a moisturizing vehicle. In the BPO monotherapy group (n=92), the reduction in noninflammatory lesions was 30% (P≤0.02). The group using only clindamycin (n=89) had a mean reduction of 9% in noninflammatory lesions (P≤0.02). A total of five pivotal trials studied the efficacy of clindamycin 1%/BPO 5% in a moisturizer vehicle. The clindamycin/BPO combination was compared to clindamycin 1%, BPO 5%, and vehicle alone. The pooled results demonstrated a significant decrease in the inflammatory lesion count with the clindamycin/BPO combination in a moisturizer vehicle. In three of the five studies (studies 1, 2, and 5), the reduction of inflammatory lesions was statistically significant (P≤0.05) as compared to the monotherapy treatment arms.

Tolerability of Clindamycin/BPO With Retinoids

Tanghetti and colleagues presented data on the use of retinoids with clindamycin/BPO in a moisturizing vehicle. The study, comparing clindamycin 1%/BPO 5% plus tazarotene 0.1% gel versus tazarotene 0.1% gel alone, was double-blind, randomized, and parallel in design. Patients (n=121) with moderate to severe acne were treated for 12 weeks with a once-daily application of medication.

The results indicated that the combination of tazarotene and clindamycin/BPO in a moisturizer vehicle achieved superior reduction (P≤0.01) in open and closed comedones compared with tazarotene alone from week 4 through week 12 of the study. In addition, a subanalysis of patients with the most severe acne revealed a greater reduction in papule and pustule count in patients receiving combination therapy (P=0.055).

One of the most important findings was that patients were better able to tolerate retinoid therapy when using an agent with a vehicle containing moisturizer. The group receiving combination therapy at week 4 experienced less peeling (P<0.05) than did the group treated with tazarotene alone. It appears that the moisturizer vehicle enhances efficacy of combination therapy, and tolerability of therapy increases. The clindamycin 1%/BPO 5% gel studied was formulated with an occlusive moisturizer (dimethicone) and a humectant moisturizer (glycerin). (See Dr Tanghetti’s article on page 4 for additional discussion of occlusive and humectant agents.) Ease of use is enhanced by the gel’s packaging, which makes it easy for patients to dispense the appropriate amount of medication.

Summary

Acne management with combination therapy has become the standard of care for many patients. It represents an important strategic approach to acne treatment by targeting more than one main underlying pathologic process. Current data support the enhanced efficacy of combination therapy. In addition to high efficacy, combination therapy minimizes development of bacterial resistance. The ideal approach for many patients is combination therapy using an effective vehicle to enhance compliance and tolerability.

References


Continued on page 12
Evolving Therapy in Atopic Dermatitis

Lawrence F. Eichenfield, MD

Atopic dermatitis (AD) is a chronic, inflammatory, pruritic skin disease with multiple clinical presentations. AD often is associated with increased serum immunoglobulin E (IgE) synthesis and a personal or family history of atopic disease. AD may be related to other atopic diseases such as asthma, allergic rhinitis, and urticaria. The incidence of the disease is rising; in 2004, Krafchik1 reported that the prevalence was 10% to 12% in children and 0.9% in adults.

AD has a complex etiology that includes immunologic responses, susceptibility genes, environmental triggers, and compromised skin barrier function. Traditional therapy includes general skin care measures, emollients, and antiinflammatory therapy. Recent additions to the AD armamentarium target xerosis and the compromised epidermal barrier of AD. A recently cleared non-steroidal xerox, which has demonstrated promise in antipruritic and antiinflammatory properties is now available, as are probiotic supplements. These abnormalities are available, as are probiotic supplements, which have demonstrated promise in infants with moderate to severe AD.

Causes of Atopic Dermatitis: Immunology and Bacterial Triggers

Although the cause of AD is still unknown, a great deal of progress has been made in understanding the disease. Genetic and environmental factors influence the skin “hyperreactivity” of AD, and it is more likely to develop in children if one or both parents have ever had the disorder, asthma, or hay fever. Increased IgE levels and peripheral eosinophilia are seen in some patients with AD; other disorders characterized by these changes include asthma, food allergy, and allergic rhinitis.3,4 Individuals may have different immunologic triggers, which may include xerosis, irritants and contactants, various foods, airborne allergens, stress, climate, and microorganisms.5

AD is associated with dysfunction of the immune system. A set of inflammatory cells—specifically, Langerhans’ cells and inflammatory dendritic epidermal cells—have been found in skin lesions of patients with AD and contribute to an augmented inflammatory response to a variety of stimuli.6 Patients with AD exhibit excessive T-cell activation in response to antigens. Allam and colleagues6 note that soluble factors appear to dominate the cellular infiltrate of lesions in AD patients, with interleukin-16, RANTES (regulated on activation, normal T-cell expressed and secreted chemokine), MCP4 (macrophage/monocyte chemotactic protein-4), and eotaxin shown in lesional skin.

The immunodysregulation that occurs with AD promotes inflammation, and it appears to be a systemic problem. Increased IgE levels are seen in the majority of patients with AD, while others have normal serum IgE levels.6 The pathogenesis of AD also includes dysregulation of phosphodiesterase (PDE) and cyclic nucleotide dysregulation. Elevated PDE appears to be an early change in the disease and may partially explain increased inflammatory reactivity.7

Bacterial colonization and infection, typically caused by Staphylococcus aureus and Streptococcus pyogenes, is common in patients with AD. S. aureus is present on the skin of most patients with AD,1 and a staphylococcal infection can be a trigger for AD flares, as well as serve as a super-antigen stimulant. In patients with evidence of secondary bacterial infection (such as erythema, honey-colored crusting, or pustules), topical or oral antibiotics may be helpful.7

An increasing problem that may have an impact on AD care is an infection resistant to antibiotic therapy, particularly community-acquired methicillin-resistant S. aureus (MRSA). The prevalence of MRSA varies regionally in the United States, and dictates optimum therapy for bacterial infections in patients with AD. For example, in Houston, Texas, where the prevalence of MRSA is high, bleach baths are a standard treatment for patients with AD. In most parts of the country, antibiotic therapy with a cephalosporin, dicloxacillin, or amoxicillin/clavulanate is recommended as first-line therapy for non–life-threatening, secondary skin infections. If an infection does not respond to treatment or if the patient presents with cellulitis, abscesses, or has a history of MRSA, then it is prudent to change the therapeutic approach. Bacterial cultures and sensitivity testing are suggested and, based on the results, treatment with clindamycin, trimethoprim/sulfamethoxazole, or another antibiotic to which the bacteria are sensitive is recommended. The oral, bacteriostatic agent linezolid is an alternative. If the infection is severe or life-threatening, intravenous vancomycin may be used.

The influence of allergy triggers on patients with AD is controversial. Allergic reactions to food, dust mites, and other factors are more common in AD patients compared to individuals without AD. Sensitivity to allergens is considered a trigger of eczematous dermatitis in a subset of children with the disease.7 Manifestations of allergy also include contact urticaria, generalized urticaria, nasal congestion, wheezing, and gastrointestinal effects.8 When clinical allergy is suspected, a radioallergosorbent test or referral to an allergist is recommended.

Skin Barrier Dysfunction

Patients with AD have abnormalities in skin barrier function. These abnormalities include increased transepidermal water loss, decreased stratum corneum moisture content, and other associated characteristics (Table).7

Emerging Insights and New Therapeutic Opportunities: Acne and Atopic Dermatitis
Research has identified some key mechanisms of epidermal barrier function and dysfunction in AD. One factor in the development of AD in some patients appears to be related to stratum corneum chymotryptic enzyme (SCCE). SCCE serves as a protease that can damage epidermal cell-cell adhesion. Inhibitors occur naturally in the skin to block proteases from destroying barrier function. In a subset of patients, barrier dysfunction appears to be mediated by variations in the SCCE gene, causing increased SCCE activity that “over-powers” the protease inhibitors. Researchers continue to explore how barrier dysfunction and breaks in the skin allow an entryway for antigens that may trigger the inflammatory response.

Historically, there are variations in expert recommendations for bathing in patients with AD. Some recommend the avoidance of baths and frequent application of emollients to moisturize the skin. Other experts emphasize the usefulness of bathing for hydrating skin in AD, suggesting bathing once to several times a day for several minutes in warm water followed by topical medication and moisturizer application. Some recent studies have compared methods of bathing and skin care, and the results of these investigations should be published soon.

Clearly, a trend in AD therapy is to target xerosis and compromised epidermal barrier function. Researchers are exploring selected emollients and vehicles that will enhance barrier function. The trend in this field is toward the use of new formulations and prescription products that are going through the US Food and Drug Administration approval process as “devices.”

Table. Barrier Function Abnormalities Associated With Atopic Dermatitis

- Increased transepidermal water loss
- Decreased stratum corneum moisture content
- Increased permeability to hydrophilic substances
- Decreased lipids/ceramides
- Decreased barrier to infectious agents
- Decreased endogenous humectants
- Likely increased epicutaneous antigen absorption

### Efficacy of Nonsteroidal Prescription Creams

N-Palmityloethanolamine (PEA) non-steroid cream, (MimyX) appears to be a useful agent in the treatment of AD. It contains natural lipids, including olea europaea, palm glycerides, hydrogenated lecithin, and squalene. The active agent, PEA, is a naturally occurring essential fatty acid with antiinflammatory properties. PEA does not contain emulsifiers that may disrupt the epidermis. Further, it appears to improve stratum corneum repair and promote skin hydration, and it may modify lipids in the skin.

A large study of more than 2,400 patients with AD demonstrated the efficacy and tolerability of PEA nonsteroidal cream. This was an international, open-label, prospective, observational, cohort study of patients with mild to moderate AD. Over 38 days, the use of PEA cream resulted in decreased itching, dryness, erythema, lichenification, and excoriation. According to the investigators, 62% of patients who used PEA cream were able to decrease their use of concurrent topical corticosteroids, 34% discontinued using topical corticosteroids; 20% decreased their use of concurrent topical immunomodulators, and 39% discontinued using antihistamines. Sixty percent of patients reported sleep improvement, and tolerability of PEA cream was high.

Hydrolipidic cream, another non-steroidal agent, also may be useful in treating AD. The active agent, glycyrrhetinic acid, appears to have anti-inflammatory and anti-itch properties. Glycyrrhetinic acid has been shown to inhibit 11β-hydroxysteroid dehydrogenase, an enzyme responsible for glucocorticoid metabolism. Inhibiting this enzyme prevents inactivation of natural hydrocortisone. In addition, glycyrrhetinic acid indirectly potentiates the effect of topical corticosteroids on an individual’s endogenous corticosteroids. Hydrolipidic cream also contains sodium hyaluronate, which hydrates the skin. However, clinicians and patients are advised that this agent contains shea butter, which is extracted from shea nuts, so individuals who are allergic to nut oil may react to this compound.

In a 5-week study of 30 adult patients with mild to moderate AD, hydrolipidic cream was compared to vehicle (an emollient base minus active ingredients). Compared to vehicle alone, the hydrolipidic cream significantly improved the outcome variables including total body affected area, Eczema Area and Severity Index (EASI) score, and itch score. In a recently completed double-blind, randomized study of 218 patients, hydrolipidic cream significantly improved the EASI score and itch score and the need for rescue medication was decreased.

Probiotics also have been studied and have been stated to be beneficial in patients with AD. A recent study from Perth, Western Australia, investigated the effects of probiotics on moderate or severe AD in 53 young children between 6 and 18 months of age. The patients were given a probiotic (Lactobacillus fermentum) or placebo, twice daily for 8 weeks. The final evaluation was done at week 16. The results were measured by the Severity Scoring of Atopic Dermatitis (SCORAD) index. Reduction in the SCORAD index was significant in the probiotic group compared to the placebo group (P=0.03). At week 16, more children receiving probiotics (n=24, 92%) had a SCORAD index that was better than baseline as compared to children in the placebo group (n=17, 63%) (P=0.01). At the end of the study, more children in the probiotic group had mild AD (n=14, 54%) than in the placebo group (n=8, 30%). However, the placebo response is very high (10.2) in this study. It seems that while the decrease in the SCORAD in the probiotic group was significant as compared to baseline, unlike the placebo group, there was no statistical difference in improvement between the two groups. Further studies will be useful to assess the utility of this intervention.

### Summary

There is an evolving understanding of AD and increasing knowledge of how atopy may be triggered in a subset of patients. Treatment of AD includes education, hydration of the skin, and antiinflammatory therapies. Nonsteroidal creams are new agents that may be effective treatment alternatives and are well tolerated by patients. Probiotic supplements may show promise in infants with AD. Barrier function is critically important in treatment decisions regarding AD, since stratum corneum repair, skin hydration, and lipid modification help alleviate symptoms. Treatment of barrier dysfunction continues to be an evolving area of therapeutic interest.
Nonsteroidal Treatment of Atopic Dermatitis
James Turner, MD, PhD

Atopic dermatitis (AD) is a chronic, cyclic, relapsing skin disorder prevalent in infants and young adults. It is the most common skin disease in childhood. Although patients often improve as they get older, AD is a disease that persists in 0.9% of adults. The prevalence of AD has increased two- to threefold over the past decade. Currently, more than 15 million people in the United States have AD symptoms.

Individuals with AD experience disruption of skin barrier function that leads to increased antigen absorption. This contributes to increased transepidermal water loss (TEWL) and worsening of AD symptoms. Standard therapies, including emollients, corticosteroids, and topical calcineurin inhibitors (TCIs), are important in the management of this disease.

The inflammation of AD typically involves flexural and extensor areas of the skin. The areas most commonly affected are the face, inside the elbows, behind the knees, and on the hands and feet. The cycle of AD causes the skin to become extremely itchy, leading to scratching, which then causes redness, swelling, cracking, crusting, and scaling. Flares as well as remissions are common.

Because AD is a visible disease, patients are at risk for psychological difficulties and low self-esteem. Similar to psoriasis and other severe eczematous processes, AD can have extreme effects on a patient’s social interactions, success at work, sexual relationships, and overall quality of life. Family members and other caregivers experience significant burdens from the disease as well, including lack of sufficient, uninterrupted sleep and adverse effects on family dynamics and functioning.
The most important step in treating AD effectively is rehydration of the stratum corneum. Eichenfield and colleagues\(^1\) reported that regular bathing provides beneficial hydration of the skin and debride-ment of crust when supplemented with a moisturizing cleanser, followed immediately by the application of a topical medication and/or emollient to seal in water absorbed by the skin during bathing. In addition, lubrication increases the rate of healing and establishes a barrier against further drying and irritation (Table).\(^{2,6}\)

**Topical Corticosteroids**

Topical corticosteroids have long been considered first-line therapy for AD. Once the disease is controlled, topical corti-costeroids should be used intermittently, typically twice a week, to control flares.\(^1\) Combination therapy with nonsteroidal topical immunomodulatory agents—that is, TCIs—is common. The goal is to taper the use of topical corticosteroids so that patients use nonsteroidal agents alone.

The potential for side effects, complicated by patients’ fears of corticosteroid use, necessitates safer topical treatment options.\(^{15}\) In a questionnaire-based study of 200 dermatology outpatients with atopic eczema ranging in age from 4 months to 68 years, 73% of respondents were concerned about using topical corticosteroids on their own or their child’s skin, and 24% admitted to having been noncompliant with treatment because of safety concerns.\(^{16}\) These results underscore the need for safer therapeutic alternatives to improve compliance, limit steroid use, and extend periods of remission.\(^{3,5,5}\)

**Topical Calcineurin Inhibitors**

Tacrolimus and pimecrolimus are non-steroidal topical immunomodulatory agents that suppress T-lymphocyte activity and inhibit calcineurin in the skin.\(^{17}\) These TCIs are recommended for second-line, short-term, intermittent treatment of AD in cases in which corticosteroids would be needed to control the disease.\(^8\) Tacrolimus 0.03% ointment is indicated for moderate to severe AD and pimecrolimus 1% cream is indicated for mild to moderate AD in patients over 2 years of age. TCIs are particularly effective in treating facial and intertriginous areas of the body where there is a greater risk of topical cortico-steroid-induced atrophy.\(^{19,20}\) The most commonly reported side effects of these agents are burning, stinging, and itching in the initial stages of treatment.\(^{3,19-22}\) A topical corticosteroid may be added to therapy to minimize discomfort.

**The goal of [atopic dermatitis] (AD) treatment is to target underlying skin abnormalities such as xerosis, pruritus, superinfection, and inflammation, and to prevent flares.**

In March 2005, a black-box warning was issued by the US Food and Drug Administration for tacrolimus and pimecrolimus resulting from animal studies showing an increased risk of skin cancer. Although it will take years to accurately assess cancer risk in humans, physicians should counsel patients regarding sun avoidance and appropriate use of sunscreens.\(^{1,18}\)

**Phototherapy, Antihistamines, and Antibiotics**

Eichenfield and colleagues\(^1\) found that phototherapy is effective in adult AD patients, but efficacy and safety data in the pediatric population are limited. Data regarding the efficacy of oral antihista-mines are inconclusive. Antihistamines may provide relief of pruritus through unknown mechanisms and, thus, may help patients sleep. Topical or oral antibiotics are effective in treating secondary bacterial infections, but long-term use of antibiotics is not recommended.

**Nonsteroidal Cream Device**

PEA nonsteroidal cream (PEA cream) represents a new class of corticosteroid-free, TCI-free topical therapy for AD patients. There are no restrictions on patient age or duration of treatment with the use of PEA cream. This nonsteroidal cream has been shown to relieve the major symptoms of AD, including xerosis, pruritus (and associated excoriation), scaling, erythema, and lichenification.\(^{23}\) It repairs the skin barrier dysfunction common to AD patients, thereby helping to prevent exposure to environmental triggers.\(^{3,23}\) PEA cream mimics the lamellar structure of the skin barrier and replenishes the skin with natural lipids, including PEA.\(^{24}\) The addition of PEA cream to a corticosteroid treatment regimen reduces the risk of relapse in patients with chronic AD.\(^{25}\)

In a large-scale study,\(^{23}\) PEA cream was shown to be effective in managing AD symptoms in 923 pediatric patients between 2 and 12 years of age. The study demonstrated significant corticosteroid-sparing effects. Many patients discontinued topical corticosteroids or were able to use less potent corticosteroid agents and formulations. PEA cream was well tolerated by patients and was shown to be safe and effective.

In a recent study,\(^{25}\) the efficacy of PEA cream plus emollient was compared to that of emollient alone (as the control) in reducing the risk for relapse in patients with chronic AD. In this multicenter, investigator-blinded, vehicle-controlled trial, efficacy and start of flare was determined by assessment of erythema, pruritus, and population/induration/edema. The patients in group 1 applied the nonsteroidal cream/emollient combination on one side of the body and emollient alone on the opposite side. In group 2, application of agents on each side of the body was reversed. The study included 74 chronic AD patients, 7 to 61 years of age. Topical steroids were administered only in the event of flare.

The results showed that addition of the nonsteroidal cream/emollient resulted in an extended median time until flare. The median time to flare was 43 days for skin treated with PEA nonsteroidal cream/emollient and 29 days for skin treated with emollient only. Differences in duration of flare were not significant. There was a 25% greater incidence of flare with emollient only versus skin treated with nonsteroidal cream (P<0.051). No serious adverse events were reported.\(^{25}\)

**Summary**

AD is a chronic, relapsing disease that has extreme effects on the quality of life of patients and their families. Patients with AD typically have skin barrier dysfunction that leads to worsening of AD symptoms. Standard therapies include emollients, corticosteroids, and TCIs.

Continued on page 12
Combination Therapy Considerations in Acne Vulgaris

Continued from page 7

13. Oh CW, Myung KB. An ultrastructural study of the disrupted skin barrier and replenishment properties has shown benefits in treating AD, including repair and restoration of skin lipid levels. It is a safe, effective, and well-tolerated therapy for AD patients of all ages and it reduces the need for additional therapies. Adding PEA nonsteroidal cream to corticosteroid therapy leads to longer remissions, has a corticosteroid-sparing effect, and represents a significant advance in current treatment options for AD.

Nonsteroidal Treatment of Atopic Dermatitis

Continued from page 11

Attention to vehicle and barrier function is essential in the search for a safe and effective treatment regimen for AD. A new nonsteroidal cream with antiinflammatory properties has shown benefits in treating AD, including repair and restoration of disrupted skin barrier and replenishment of skin lipid levels. It is a safe, effective, and well-tolerated therapy for AD patients of all ages and it reduces the need for additional therapies. Adding PEA nonsteroidal cream to corticosteroid therapy leads to longer remissions, has a corticosteroid-sparing effect, and represents a significant advance in current treatment options for AD.

References